Arcturus signs definitive agreement to acquire computational biology firm myNEO to bolster AI-driven mRNA design and target identification capabilities
- Arcturus reported encouraging interim Phase 2 results for ARCT-810 in OTC deficiency.
- Favorable FDA feedback allows next-generation LUNAR 2.0 candidate ARCT-2601 to join the ongoing ARCT-810 study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.